Production Linked Incentive Scheme
1. At a Glance
- PLI Scheme is an outcome-linked, output-based subsidy programme giving incentives (typically 4–6% of incremental sales) to manufacturers in 14 strategic sectors to make India a global manufacturing hub under Atmanirbhar Bharat [S1][S2].
- Total committed incentive outlay: ₹1.97 lakh crore (~US$26 bn) across 14 sectors notified between Mar 2020 and Sep 2021 [S1][S2].
- Marks a paradigm shift from input-based subsidies (capex grants, tax holidays) to performance-linked disbursal tied to incremental production, investment and sales [S2].
2. Why in the News
- Mar 2026 PIB note on PLI for Bulk Drugs (KSMs/DIs/APIs) — 33 of 41 products subscribed, 48 greenfield projects approved, actual investment of ₹4,814.1 crore against committed ₹4,329.95 crore; outlay ₹6,940 crore, tenure FY2022-23 to FY2028-29 [S5].
- Aug 2025 PIB Background Paper "PLI Scheme: Powering India's Industrial Renaissance" reported cumulative investment > ₹1.76 lakh crore (Mar 2025) and 806 applications approved [S2][S4].
- May 2026 update: 836 applications approved, cumulative sales > ₹20.41 lakh crore, exports > ₹8.3 lakh crore, 14.39 lakh direct + indirect jobs created [S1].
3. Background & Evolution
- Mar 2020: First PLI launched for Bulk Drugs, Medical Devices and Mobile Manufacturing (Large-Scale Electronics) [S3].
- Nov 11, 2020: Union Cabinet approved PLI for 10 additional sectors with outlay ~₹1.46 lakh crore [S3].
- Sep 2021: PLI extended to Drones, Textiles (MMF & technical), Auto & Auto Components, ACC battery, Semiconductors, taking total to 14 sectors [S1].
- Aligned with National Manufacturing Policy 2011 target of raising manufacturing's share in GDP to 25%.
4. Core Static Facts
- Nodal coordinator: Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce & Industry; sector schemes run by respective line ministries [S2].
- Total outlay: ₹1.97 lakh crore (₹1.91 lakh crore incentive + administrative) [S1].
- Tenure: Mostly 5 years per sector (some up to FY2028-29 e.g., Bulk Drugs) [S5].
- 14 Sectors (administering ministry):
- Mobile/Large-Scale Electronics, IT Hardware, Telecom & Networking, Electronic/Tech Products — MeitY/DoT [S1].
- Bulk Drugs (APIs/KSMs/DIs), Medical Devices, Pharmaceuticals — Dept of Pharmaceuticals [S5].
- Auto & Auto Components, ACC Battery, Drones — Ministry of Heavy Industries [S1].
- Food Processing — MoFPI; Textiles (MMF + technical) — Min. of Textiles; Specialty Steel — Min. of Steel; White Goods (AC + LED) — DPIIT; High-Efficiency Solar PV — MNRE [S1].
- Performance (Dec 2025 cum.): 836 approved applications; investment ₹2.16 lakh crore; sales ₹20.41 lakh crore; exports ₹8.3 lakh crore; jobs 14.39 lakh [S1].
- Bulk Drugs PLI: ₹6,940 crore outlay; 41 products; 33 subscribed; 48 greenfield projects [S5].
5. Multi-Dimensional Analysis
- Economic: Shifts India up global value chains; reduces import dependence in APIs (China ~70%), electronics, and energy storage; mobile exports crossed ₹2 lakh crore largely due to PLI [S1][S2].
- Strategic/Geopolitical: Bulk Drugs PLI explicitly aims to "mitigate supply-chain risks from single-source dependence" (i.e., China) — flagged post-COVID disruption [S5]. Semiconductor & ACC battery PLIs align with Quad supply-chain resilience and net-zero 2070 goals.
- Administrative: Sunset-based, performance-gated disbursal; mid-course recalibration (e.g., IT Hardware PLI 2.0 in May 2023 with enhanced ₹17,000 cr outlay) [S2].
- Sectoral concentration: Mobile manufacturing alone accounts for disproportionate share of investment/exports — raising questions on broad-based industrialisation [S2].
- Fiscal: Disbursals slower than committed — only a fraction of ₹1.97 lakh crore actually paid out, since payouts depend on meeting incremental thresholds [S1].
6. Recent Developments
- Mar 2026: PIB confirms 48 greenfield API projects approved; ₹4,814 cr actual investment in Bulk Drugs PLI [S5].
- 2025: PLI Scheme Background Paper released; cumulative figures revised upward [S2].
- May 2025: Cabinet approved enhanced PLI budget allocations to accelerate disbursal [S4].
- 2024–25: 755 → 836 approved applications; investment crossed ₹2 lakh crore mark [S3][S1].
7. Prelims Hooks
- PLI Scheme covers 14 sectors (not 13 or 15) [S1].
- Total incentive outlay: ₹1.97 lakh crore [S1].
- First three PLI sectors (Mar 2020): Bulk Drugs, Medical Devices, Mobile Manufacturing [S3].
- Nodal department: DPIIT under Ministry of Commerce & Industry [S2].
- Bulk Drugs PLI outlay: ₹6,940 crore; 41 critical products; tenure FY2022-23 → FY2028-29 [S5].
- ACC Battery PLI is administered by the Ministry of Heavy Industries [S1].
- Solar PV (High Efficiency Modules) PLI is administered by MNRE [S1].
- Drones PLI sits under Ministry of Civil Aviation/MHI [S1].
- Cumulative exports under PLI > ₹8.3 lakh crore (2025) [S1].
- Approved applications: 836 (Dec 2025) [S1].
- Incentive rate is typically 4–6% of incremental sales over a base year [S2].
- Aligns with target of raising manufacturing's GDP share to 25% (National Manufacturing Policy 2011).
- PLI is outcome-based — no upfront capex grant [S2].
8. Mains Relevance
- GS-III — Indian Economy: Industrial Policy, Mobilisation of Resources; Effects of Liberalisation on the Economy.
- GS-II — Government Policies & Interventions for Development.
- Possible Mains stems: 1. "PLI marks a paradigm shift from input-based to outcome-based industrial subsidies. Critically examine its effectiveness in achieving Atmanirbhar Bharat." (250 words) 2. "Discuss how the PLI Scheme for Bulk Drugs addresses India's strategic vulnerability in pharmaceutical supply chains." (150 words) 3. "Has the PLI Scheme broadened India's manufacturing base or merely concentrated gains in a few sectors? Evaluate." (250 words)
9. Related Topics to Study Next
- National Manufacturing Policy 2011 — sets the 25% GDP target PLI operationalises.
- Make in India (2014) — umbrella initiative within which PLI sits.
- Semiconductor Mission (ISM) & SPECS — companion electronics-manufacturing programme.
- Atmanirbhar Bharat Abhiyan — overarching policy framework.
- National Logistics Policy 2022 & PM Gati Shakti — complementary supply-chain push.
- WTO Subsidies & Countervailing Measures Agreement — examines whether PLI is WTO-compliant (export-contingent concerns).
- FDI policy in manufacturing — interacts with PLI investment commitments.
- National Green Hydrogen Mission / ACC Battery — sectoral overlaps for energy transition.
10. Common Errors / Trap Areas
- PLI is NOT a tax exemption or capex subsidy — it is a post-production cash incentive [S2].
- DPIIT coordinates, but disbursing ministries differ by sector — e.g., ACC Battery is not under MNRE but MHI [S1].
- Number of sectors is 14, not 13; the Drones, Textiles (MMF), Auto, Semiconductors, ACC batch was added later (2021), not in the original 2020 list [S1][S3].
- Bulk Drugs PLI = 41 products; do not confuse with the separate Pharmaceutical PLI (formulations) which has a ₹15,000 cr outlay [S5][S1].
- Tenure varies by sector — Bulk Drugs runs till FY2028-29, not the generic 5-year horizon [S5].
11. Sources
- [S1] Production Linked Incentive Scheme with ₹1.91 Lakh Crore Outlay Drives Strong Industry Participation Across 14 Strategic Sectors — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2230621 — (tier 1)
- [S2] PLI Scheme: Powering India's Industrial Renaissance (Background Paper, Aug 2025) — https://static.pib.gov.in/WriteReadData/specificdocs/documents/2025/aug/doc2025824619301.pdf — (tier 1)
- [S3] 755 applications approved across 14 sectors, investment of Rs. 1.23 lakh crore attracted under PLI Scheme till March 2024 — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2039119 — (tier 1)
- [S4] Government Scales Up PLI Budget to Accelerate Manufacturing — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2107825 — (tier 1)
- [S5] PLI Scheme for Bulk Drugs — Department of Pharmaceuticals (13 Mar 2026) — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2239574 — (tier 1)